Boehringer Ingelheim, Hikma Pharmaceuticals deal

Hikma completed its acquisition of assets of the Bedford Laboratories U.S. generic injectables business of Boehringer’s Ben Venue Laboratories Inc. subsidiary. Ben Venue received $225 million in cash ...